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Summary The expression of mRNA for the epidermal growth factor (EGF) receptor, EGF and transforming
growth factor a (TGF-a) was determined in 76 malignant, six borderline and 15 benign primary ovarian
tumours using the reverse transcriptase-polymerase chain reaction and related to clinical and pathological
parameters. Of the malignant tumours, 70% (53/76) expressed EGF receptor mRNA, 31% (23/75) expressed
EGF mRNA and 35% (26/75) expressed TGF-a mRNA. For the borderline tumours, four of six (67%)
expressed EGF receptor mRNA, 1/6 (17%) expressed TGF-a mRNA and none expressed EGF mRNA.
Finally, 33% (5/15) of the benign tumours expressed EGF receptor mRNA, whereas 40% (6/15) expressed
EGF mRNA and 7% (1/15) expressed TGF-a mRNA. The presence of the EGF receptor in malignant
tumours was associated with that of TGF-a (P = 0.0015) but not with EGF (P= 1.00), whereas there was no
relationship between the presence of EGF and TGF-a (P = 1.00). EGF receptor mRNA expression was
significantly and positively associated with serous histology (P= 0.006) but not with stage or grade. Neither
EGF nor TGF-a showed any link with histological subtype or stage. The survival of patients with malignant
tumours possessing EGF receptor mRNA was significantly reduced compared with that of patients whose
tumours were negative (P = 0.030 for all malignant tumours; P= 0.007 for malignant epithelial tumours only).
In contrast, neither the expression of TGF-a nor EGF was related to survival. These data suggest that the
presence of EGF receptor mRNA is associated with poor prognosis in primary ovarian cancer.
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Ovarian cancer is the most fatal gynaecological cancer in the
UK, resulting in approximately 4000 deaths per annum (La
Vecchia et al., 1992). The biological factors that regulate the
growth of this disease are poorly defined, although evidence
is accumulating that members of the epidermal growth factor
(EGF) family are implicated in the regulation of cell
proliferation in ovarian tumours. In epithelial cells, both
EGF and its structural homologue, transforming growth
factor a (TGF-a) stimulate proliferation. TGF-a is a 50
amino acid protein that binds to the EGF receptor, and
produces biological effects barely distinguishable from those
of EGF. Although TGF-a was named for its ability to
transform certain types of cells in culture, it is produced by
normal as well as malignant cells (Berchuck and Bast, 1993).
The EGF receptor is a 170 kDa glycosylated membrane-
spanning protein that has served as a prototype for studies of
tyrosine kinase receptors. Both EGF and TGF-a bind to the
extracellular domain of the EGF receptor with equal affinity
(Berchuck and Bast, 1993). Using model systems of ovarian
cancer, EGF and TGF-a have been shown to be growth
stimulatory to ovarian cancer cells in vitro (Morishige et al.,
1991; Rodriguez et al., 1991; Scambia et al., 1991; Crew et
al., 1992; Zhou and Leung, 1992). Antibodies directed against
either TGF-a or the EGF receptor can inhibit the
proliferation of ovarian cancer cell lines that both produce
TGF-cx and possess the EGF receptor; this is consistent with
an autocrine growth stimulation pathway (Morishige et al.,
1991; Jindal et al., 1994). Previous studies investigating the
presence of EGF receptor in ovarian tumours, using either
ligand binding (Bauknecht et al., 1988; Battaglia et al., 1989;
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Morishige et al., 1991; Owens et al., 1991a; Henzen-Logmans
et al., 1992) immunohistochemical technology (Berchuck et
al., 1991; Morishige et al., 1991; Henzen-Logmans et al.,
1992) or both (Owens et al., 1992), have indicated that this
receptor is commonly present with incidence rates varying
from 33% to 75% (Bauknecht et al., 1988, 1993; Battaglia et
al., 1989; Berchuck et al., 1991; Morishige et al., 1991; Owens
et al., 1991a; Henzen-Logmans et al., 1992). The levels of
EGF receptor have been claimed to be higher in malignant
ovarian tumours than in benign tumours or the normal ovary
(Berns et al., 1992; Owens and Leake, 1993) but perhaps the
strongest suggestion of a biological role for EGF-like factors
derives from reports that the presence of EGF receptor
protein in ovarian tumours may be related to patient
prognosis (Bauknecht et al., 1988; Battaglia, 1989; Foekens
et al., 1990; Berchuck et al., 1991; Scambia et al., 1992),
although this has not been a universal finding (Bauknecht et
al., 1990; Van der Burg et al., 1993).
In the present study, we have examined the mRNA
expression of the EGF receptor, EGF and TGF-oc using the
reverse transcriptase-polymerase chain reaction (RT-PCR)
in 97 ovarian tumours. The expression of these growth
factors and their receptors has been related to clinical and
pathological parameters to evaluate further the role of the
EGF receptor and its ligands in ovarian disease.
Patients and methods
Patients
Ovarian tumour material was collected from patients
undergoing surgery at the Eastern General Hospital,
Edinburgh, the Royal Infirmary of Edinburgh and the
University Hospital, Turin. A total of 97 patients with
histologically confirmed primary ovarian tumours were
included in this study. The 97 tumours included 76
malignant, six borderline and 15 benign tumours. The
malignant group consisted of 35 serous, 22 endometrioid,&-R EGF receptor mRNA in ovarian cancer
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five mucinous, five clear-cell carcinomas, three malignant
mixed mesodermal tumours and six others including a steroid
cell tumour, a teratoma, a mullerian tumour, two undiffer-
entiated tumours and one of mixed histologies. Ovarian
cancer patients were staged according to the International
Federation of Gynecologists and Obstetricians (FIGO)
criteria (1987). The staging system defined by FIGO assumes
that an adequate staging operation has been performed
(Cannistra, 1993). The staging operation included collection
of ascites or peritoneal washing from the pelvis, gutters and
diaphragms for cytological studies; total abdominal hyster-
ectomy plus bilateral salpingoophorectomy; infracolic omen-
tectomy and appendectomy; selective pelvic and para-aortic
lymphadenectomy and debulking of all gross disease. If
obvious macroscopic tumour was not present, biopsy of any
lesion suspect for tumour metastasis or any adhesion adjacent
to the primary tumour; blind biopsies of bladder peritoneum
and cul-de-sac, right and left paracolic gutter and pelvic side
walls; biopsy or smear of right hemidiaphragm, were
performed. Survival data were available for 70 of the 76
patients with malignant tumours. Of these, 44 patients
received cisplatin-containing regimens, seven received chlor-
ambucil monotherapy and one was treated with 32P
intraperitoneal radiotherapy. Eighteen received no further
treatment after surgery (mainly stage Ta, grade 1 disease). No
patient received therapy before surgery.
Tumour samples
Tumour samples were collected at the time of primary
surgery, were frozen in liquid nitrogen and stored at -180°C
until used. Tumour histology and grade were assessed on
paraffin-embedded sections and classified according to WHO
criteria (Serov and Scully, 1973).
mRNA extraction
Before RNA extraction 400 mg of tumour tissue was
homogenised using a tissue dismembranator (Braun, Ger-
many) at -20°C. Total cellular RNA was extracted from
frozen tissue using the lithium chloride-urea method (Bartlett,
1992). Pelleted RNA was resuspended in diethyl pyrocarbo-
nate-treated water (DEPC water) and the concentration
assessed by measuring absorbance at 260 and 280 nm.
RT-PCR
RT-PCR for EGF receptor, EGF, TGF-a and y-actin were
carried out using a Techne PHC-3 thermocycler. For the
reverse transcription assay, 20 Mg aliquots of total cellular
RNA were reverse transcribed by incubation with 300 ng of a
random hexamer oligonucleotide with 2 mM each of dATP,
dTTP, dCTP and dGTP (Pharmacia, UK), 200 units of
Superscript reverse transcriptase (Life Technologies, Paisley,
UK) for 1 h at 42°C in a total volume of 20 pl. Reverse-
transcribed RNA was stored at -20°C before analysis by
PCR.
For all PCRs, 0.2-1 1l of reverse transcribed RNA was
added to 100 ng of each primer in a volume of 50 ul. Before
PCR, this reaction was heated to 94°C for 10 min and then
cooled rapidly to 4°C. PCR reactions were performed in a
final volume of 100 Mul containing the following: 0.5 units of
Taq polymerase (Promega, Southampton, UK), 1.25 Mm
dATP, dTTP, dCTP and dGTP (Pharmacia, UK), 100 ng
of each primer, 50 mM potassium chloride, 10 mM Tris-HCl,
0.1% Triton-X and 2.5 mm magnesium chloride. Reactions
were overlaid with 100 MI of paraffin oil.
The amplification reaction was carried out over 40 cycles
with the following parameters: step 1, 94°C for 38 s; step 2,
50°C for 53 s; step 3, 72°C for 68 s. For the final cycle, the
72°C step was extended to 7 min to ensure that all transcripts
were full length. The primers used in these reactions are listed
in Table I.
PCR products were visualised after electrophoresis on
polyacrylamide gels and staining with ethidium bromide.
Tumours were scored as positive for EGF receptor, EGF or
TGF-cx when a PCR product of the correct molecular size
was amplified and identified (by eye) following electrophor-
esis. Samples were sized using a 100 bp ladder (Gibco, UK).
As an additional control, PCR of a known housekeeping
gene y-actin was performed to establish the integrity of
transcribed RNA.
The identities of transcript sequences were confirmed by
Southern blot analysis using specific [32P]5'-end labelled
probes (25-mers) targeted to unique sequences within the
transcripts (Table I).
Statistics
Differences between subgroups in contingency tables were
analysed by the Fisher's exact test. Differences of survival
used the graphical Kaplan-Meier method and groups were
compared using the log-rank test. To assess if the mRNA
variables were independently prognostic for survival Cox
regression analysis was used with stage, residual disease,
grade and histology included among the variables in the
initial step of a backward stepwise selection procedure. The
results are given as hazard ratios. A hazard ratio of 2 for a
given marker indicates that the risk of death at any time for a
patient with that marker is twice that of a patient without the
marker, all other prognostic variables being the same (Cox,
1972).
Table I Oligonucleotide primers and probes used for mRNA phenotyping of EGF receptor, EGF and TGF-cx in primary ovarian tumours
mRNA Primer/probe Sequences Positiona Transcript size
EGF receptor Sense primer 5'-ACCTGCGTGAAGAAGTGTCC-3' 442-461 516
Antisense primer 5'-CACATCTCCATCACTTATCTCC-3' 936-957
Oligonucleotide probe 5'-CATCAGTGGCGATCTCCACATCCTG-3' 666-690
EGF Sense primer 5'-TGGTTGTGGTTCATCCATTGGC-3' 2628-2649 501
Antisense primer 5'-GGCAGACATAACCACCTTCG-3' 3109-3128
Oligonucleotide probe 5'-GTTGATCTAAAGAACCAAGTAACAC-3' 2816-2846
TGF-a Sense primer 5'-GTAAAATGGTCCCCTCGG-3' 30-48 355
Antisense primer 5'-GTGATGATAAGGACAGCCAGGG-3' 363-384
Oligonucleotide probe 5'-TAATGACTGCCCAGATTCCCACACT-3' 166-190
y-Actin Sense primer 5'-CAAGTTCTACAATCCAGTGC-3' 395-414 474
Antisense primer 5'-ACGAGACCACCTTCAACTCC-3' 849-868
aBase pair positions are from sequences cited in the GenBank/EMBL data bank. Accession numbers for these sequences are as follows: EGF
receptor, X00663; EGF, X04571; TGF-a, K03222; y-actin, M16247.Results
Incidence of mRNA expression for EGF receptor, EGF and
TGF-a in ovarian tumours
All 97 ovarian tumours were analysed by RT-PCR for the
presence of EGF receptor mRNA and 96 of these for the
presence of EGF mRNA and TGF-oc mRNA. An example of
a typical RT-PCR gel is shown in Figure 1 and confirmation
of the sequence of the transcript was obtained by use of a
32P-labelled probe, targeted to a unique sequence within the
transcript (illustrated in Figure 1). Of the malignant tumours,
70% (53/76) were positive for EGF receptor mRNA, 31%
(23/75) were positive for EGF mRNA and 35% (26/75) for
TGF-oc mRNA. Analysis of co-expression of receptor and
ligand indicated that there was an association between the
presence of mRNA for the EGF receptor and TGF-a mRNA
(P=0.0015) but not between EGF receptor and EGF
(P= 1.00) (Table II). There was no association between the
presence of mRNA for TGF-cL and EGF (P= 1.00) (Table II).
Of the six borderline tumours investigated, none expressed
mRNA for EGF, while only one of six expressed TGF-ax
mRNA, however four of six expressed mRNA for EGF
receptor. Fifteen benign tumours were also investigated,
including seven of epithelial origin (five mucinous, one serous
and one Brenner), three fibromas, one thecofibroma, one
thecoma, two granulosa cell tumours and one mature cystic
teratoma. Five of these 15 tumours contained EGF receptor
EGF receptor mRNA in ovarian cancer
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mRNA. This was significantly different from the 70%
incidence found for malignant tumours (P=0.016). Expres-
sion of EGF mRNA was found in 40% (6/15) benign
tumours, which was similar to the level found in malignant
tumours, while expression of TGF-oa was observed in only 1/
15 cases, significantly lower than the expression rate of 35%
observed in the malignant group (P=0.033).
Relationship of mRNA expression to clinicopathological
features
The relationship between expression patterns and histology in
malignant tumours is shown in Table III. EGF receptor
mRNA expression was significantly more strongly associated
with serous histology than other subtypes (P=0.006). In
contrast, neither EGF nor TGF-a mRNA expression showed
any association with histological subtype (Table III). None of
these three mRNAs demonstrated any association with stage,
amount of residual disease or grade of differentiation.
mRNA expression and prognosis
The relationship between mRNA expression and survival was
investigated in the malignant group overall (survival data
available for 70 of the 76 patients) and in the epithelial
malignant subgroup (n=60) (Table IV). For the malignant
group overall, the presence of EGF receptor mRNA
a
516 -'
1 2 3 4 5 6 7 8
b
2 3 4 6 7 8
Figure 1 EGF receptor mRNA expression in primary ovarian tumours. (a) RT-PCR agarose gel wherein cDNA was reverse-
transcribed from tumour RNA and amplified using primers shown in Table I. Lane I contains DNA molecular weight markers,
lanes 2-7 contain DNA from ovarian tumours and lanes 3, 5 and 7 show a band at 516 consistent with EGF receptor amplified
cDNA. Lane 8 is a negative control containing the PCR reaction mix in the absence of tumour. (b) Confirmation of EGF receptor
transcript by Southern blot analysis using a specific 5'-32P-labelled probe. Lanes 3, 5 and 7 correspond to the same lanes in the top
panel and show the presence of a transcript.EGF receptor mRNA in ovarian cancer
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Table II Relationships between EGF receptor, EGF and TGF-a mRNA expression
TGF-a expression EGF expression
Positive Negative Positive Negative
EGF receptor positive 24 28 16 36
P=0.0015 P= 1.00
EGF receptor negative 2 21 7 16
TGF-ac positive 8 18
P= 1.00
TGF-a negative 15 34
P values obtained using Fisher's exact test.
Table III Relationship between mRNA expression and clinicopathological parameters
EGF receptor EGF TGF-ax
Parameter Positive Negative P-value Positive Negative P-value Positive Negative P-value
Histology
Serous 30 5 9 26 15 20
Endometrioid 14 8 0.006a 6 15 0.46a 7 14 0.22a
Mucinous 3 2 1 4 2 3
Clear cell 1 4 1 4 1 4
MMMT 3 0 3 0 0 3
Others 2 4 3 3 1 5
Stage
I/II 14 11 10 15 5 20
III/IV 40 10 0.054 14 35 0.43 21 28 0.072
Residual disease
<2 cm 27 15 0.18 15 27 0.44 14 28 0.80 >2cm 23 5 0.8 7 20 10 17 08
aComparison of serous vs rest (Fisher's exact test); for a few tumours, data on patient stage and amount of
residual disease were not available; similarly for one ofthe endometrioid tumours, data were obtained for EGF
receptor mRNA but not EGF or TGF-a mRNA.
expression was significantly associated with reduced survival
(P=0.030), while there was no association between the
presence of EGF (P=0.33) or TGF-a (P=0.45) and
survival. Data on clinical parameters for this group of
patients are also shown in Table IV. Of these, stage and
amount of residual disease have the most significant effects
on survival (for both, P<0.001).
Analysis of the patients with epithelial ovarian cancer
(serous, endometrioid, mucinous and clear cell carcinomas)
who make up almost 90% of the malignant group, indicated
a more significant association of the EGF receptor mRNA
with reduced survival (P=0.007) (Figure 2). As with the
malignant group overall, the association between survival
with EGF mRNA (P=0.113) and TGF-a (P=0.119) was
non-significant, whereas stage, amount of residual disease,
grade and histology were all linked to survival in this group
of patients (Table IV). To assess if mRNA expression was
independently prognostic for survival, Cox regression analysis
was used. The hazard ratio for expression of EGF receptor
mRNA alone in a Cox model is 3.9 (standard error=2.0).
Using only biological variables (i.e. omitting debulk), results
for the Cox model are shown in Table V (62 patients, 33
events) and a hazard ratio of 2.5 for expression of EGF
receptor mRNA was obtained. Using all variables, both
debulk and EGF receptor mRNA expression remained in the
final Cox model with the hazard ratio for EGF receptor
being similar to that in the model above.
Discussion
Expression of the EGF receptor is now widely accepted to
confer poor prognosis in breast cancer patients, and evidence
is accumulating that such a link may exist in other solid
neoplasms including ovarian cancer (Bauknecht et al., 1988;
Battaglia et al., 1989; Foekens et al., 1990; Berchuck et al.,
1991; Scambia et al., 1992). Novel treatment strategies
targeted against the EGF receptor, are currently under
investigation. Such treatments will, ultimately, require
testing under conditions in patients known to be positive
for the EGF receptor target molecule. The use of rapid and
robust techniques for assessment of EGF receptor status is a
prerequisite for successful targeting of such treatments. In
this study, RT-PCR has been used to detect mRNA
Table IV Univariate analysis of survival
P (log-rank)
All malignant Epithelial only
Parameter Comparison n= 70 n=62
EGF receptor mRNA Positive vs negative 0.030 0.007
EGF mRNA Positive vs negative 0.33 0.11
TGF-ax mRNA Positive vs negative 0.45 0.12
FIGO stage Stage I vs stages II, III and IV <0.001 <0.001
Residual disease <2 cm vs >2 cm <0.001 <0.001
Grade Poor vs well + moderate 0.008 0.003
Histology Serous vs rest - 0.039EGF receptor mRNA in ovarian cancer
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Figure 2 Relationship between EGF receptor e
survival of patients with epithelial ovarian canc
patients whose tumours expressed EGF rec
demonstrated reduced survival compared with I
tumours were negative (P=0.007; log-rank test).
expression in primary ovarian tumours. This
the advantages of sensitivity and avoids th4
protein determination, such as masking ofrecel
or receptor internalisation. The only previ
mRNA expression for EGF receptor and TG
cancer does provide some evidence that
correlate with protein levels (Kohler et al., 1I
of the current study were to expand the currei
EGF receptor in relation to disease outcor
cancer and to do so using rapid molecular biol
to assess receptor expression.
The data presented here, together wi
published studies, indicate that both the EGI
its ligands are commonly present in ova
Previous reports of the incidence of the
protein in ovarian tumours vary between 3
when determined by ligand binding or immun
techniques (Bauknecht et al., 1988, 1993; B;
1989; Foekens et al., 1990; Berchuck et al., IS
et al., 1991; Owens et al., 1991a; Berns et al.,
Logmans et al., 1992). When mRNA for the
was examined by Northern blot analysis, it wz
present in 75% tumour samples (Kohler
Bauknecht et al., 1993). Our finding of 70%
EGF receptor mRNA is therefore consiste
reports. We found EGF mRNA present in 31
tumours, which is again consistent with the fin
and Leake (1993), who reported the protein tc
30% of malignant tumours. Our incidence of
for TGF-a mRNA is lower than the 66% incid
ac mRNA determined by Northern blot anal)
al., 1992; Bauknecht et al., 1993) or the 89%
for the protein by Owens et al. (1991b). This fin
the relative increase in sensitivity to be exp(
from the use of RT -PCR in comparison N
blotting or protein estimation. The reason
discrepancy is unclear but it is unlikely to
methodological problems since all tumours
mRNA expression of growth factors and r
first characterised for y-actin mRNA expressio
for integrity of extracted RNA. Furthermore, our ongoing
studies with ovarian carcinoma cell lines have shown that
expression of mRNA and protein for EGF, TGF-a and EGF
receptor are in concordance, suggesting that this result is not
due to an underestimation of TGF-a levels.
Investigation of a small group of 15 benign tumours
indicated that 5 of 15 contained EGF receptor mRNA. While
these numbers are small, they support the data of Owens and
Leake (1993) who reported an incidence of only 13% EGF
receptor protein positivity in benign ovarian tumours and do
suggest that malignant tumours are more likely to express the
EGF receptor than their benign counterparts.
A significant correlation was obtained between the
presence of the EGF receptor mRNA and TGF-a mRNA
4.0 5.0 in malignant tumours. This co-expression of EGF receptor
with TGF-ax but not with EGF in primary ovarian tumours
was also noted by Morishige et al. (1991) and provides a
expression and basis for suggesting that a TGF-a/EGF receptor autocrine
er. Survival of loop is present within ovarian cancer cells. This idea was
-eptor mRNA supported by experiments using neutralising antibodies that
patients whose produced growth inhibition in cultures obtained from ovarian
primary tumours or ascites if the antibodies were targeted
against TGF-a or the EGF receptor but not if targeted
against EGF (Morishige et al., 1991).
Investigation of EGF receptor mRNA expression rates in
approach has different ovarian tumour histological subtypes suggested a
e problems of stronger association between EGF receptor mRNA and the
ptors by ligand most common and aggressive pathological subtype, the
ous report of serous form. This finding is in agreement with the
F-a in ovarian observation of Morishige et al. (1991) who, using ligand
mRNA levels binding, found a higher incidence (74%-positive) of the EGF
)92). The aims receptor in serous tumours when compared with other
nt database on pathological subgroupings but contrasts with the majority
ne in ovarian of reports where no difference was identified (Bauknecht et
logy techniques al., 1988; Owens et al., 1991a; Scambia et al., 1992; Van der
Burg et al., 1993). No association was found between the
ith previously presence of EGF receptor mRNA and advanced stage in
F receptor and agreement with previous studies (Bauknecht et al., 1988;
rian tumours. Berchuck et al., 1991; Owens et al., 1991a; Van der Burg et
EGF receptor al., 1993). However, some studies (Battaglia et al., 1989;
3% and 75% Henzen-Logmans et al., 1992) have reported an increased
vohistochemical incidence of positivity in metastatic lesions as compared with
attaglia et al., primary tumours which, in turn, might suggest increased
991; Morishige expression is associated with disease progression. Perhaps the
1992; Henzen- strongest indication that the EGF receptor could play a role
EGF receptor in the course of this disease is its proposed link with
as found to be prognosis. Our findings support the view that the presence of
et al., 1992; EGF receptor mRNA is associated with reduced survival in
positivity for malignant tumours when examined by univariate analysis.
nt with these Furthermore this relationship appears to be stronger within
1% of ovarian the epithelial group, which represents 89% of this series of
iding of Owens malignant tumours. The hazard ratio for EGF receptor
be present in mRNA alone in a Cox model is 3.9. Multivariate analysis
35% positivity however demonstrated that this was not significantly
lence for TGF- independent (P =0.1) of the clinicopathological parameters
rsis (Kohler et studied. Four groups have published on the relationship of
value reported the EGF receptor protein with respect to prognosis. Berchuck
iding is despite et al. (1991), using immunohistochemical detection, demon-
ected resulting strated that the presence of EGF receptor was associated
with Northern with reduced overall survival. Scambia et al. (1992), using a
i for such a ligand binding technique, demonstrated that progression-free
be related to survival was reduced in patients with EGF receptor-positive
, assessed for tumours, again suggesting that EGF receptor positivity is
receptors were associated with a negative outcome. Other reports however
)n as a control have contradicted these findings. Van der Burg et al. (1993)
Table V Multivariate analysis of survival in epithelial cancer patients
Variable Classification Hazard ratio 95% Cl P-value
EGF receptor Positive vs negative 2.5 (0.8, 7.2) 0.1
Grade Poor vs well + moderate 2.2 (1.0, 5.1) 0.06
Stage I vs II-IV 3.5 (1.0, 12.1) 0.05
aCI,confidence interval.EGF receptor mRNA in ovarian cancer
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found no correlation between the presence of EGF receptor
protein, determined either by immunohistochemistry or
ligand binding, and progression-free survival. Furthermore,
initial studies by Bauknecht et al. suggested that patients with
EGF receptor-positive tumours had improved overall survival
(Bauknecht et al., 1988), however extension ofthis data set to
include more patients reversed this finding (Bauknecht et al.,
1990). In a subsequent report, the same authors found that
ovarian tumours expressing high concentrations of EGF
receptor and TGF-a responded better initially to chemother-
apy than those with negative or low levels of these proteins,
however recurrence was also rapid in the same group
(Bauknecht et al., 1993).
In conclusion, this is the first report on the use of RT-
PCR methodology to determine expression of the EGF
family in ovarian cancer. Expression of EGF receptor mRNA
was found to be associated with serous histology and a poor
survival. These data support the view that expression of the
EGF receptor plays a key role in the biology of this disease.
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